RxDoctor Payments Data

Sharon Lewis, MD

Neurology · Cherry Hill, NJNPI 1114082385

Payments from drug & device makers

$1,752in general payments, 2019–2025

Across 72 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$688
  • Neurelis, Inc.$221
  • Teva Pharmaceuticals USA, Inc.$147
  • UCB, Inc.$136
  • Novartis$120
  • Biohaven Pharmaceutical Holding Company Ltd.$116
  • plus $324 from 11 others

What the payments were for

  • Food & beverage$1,752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,752 in reported general payments places this provider in the 45th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$48,163
Medicare patients
188
Services billed
1,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm89$63,171
Nurtec OdtRimegepant Sulfate30$56,808
Aimovig AutoinjectorErenumab-Aooe62$49,284
UbrelvyUbrogepant35$36,258
Verapamil Er PmVerapamil Hcl16$8,961
Emgality SyringeGalcanezumab-Gnlm12$8,044
Levetiracetam41$7,154
Eletriptan HbrEletriptan Hydrobromide18$5,610
Zonisamide30$2,910
Gabapentin106$2,548
Sumatriptan Succinate49$2,428
RizatriptanRizatriptan Benzoate73$1,329
Memantine Hcl38$921
Topiramate70$892
Nortriptyline Hcl75$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$42$56,80830 claims
AbbVieUbrelvy$688$36,25835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 521 neurology providers in New Jersey.

Other neurology in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →